Global Short Bowel Syndrome Market to Benefit from the Development of New Biopharmaceuticals, Cross Promotion amongst Companies to Further Drive up Demand in the Market, TMR

ALBANY, N.Y., March 25, 2021 /PRNewswire/ -- The global short bowel syndrome market is expected to expand due to the trend of introducing better biopharmaceuticals. For example, Huons, a pharmaceutical product manufacturer, has teamed up with Genexine, Inc, a clinical-stage biotechnology company, to produce new biopharmaceuticals. Firms in the global short bowel syndrome market are working on improving their effectiveness in order to develop new options for treatment for GLP-2 drugs and growth hormone. Because short bowel syndrome is a rare disease, FDA grants are allowing companies to develop orphan drugs.

Another factor that is likely to boost the reputation of businesses working together in the global short bowel syndrome market is cross promotion. The growing demand for biobetter drugs and therapeutic drugs for uncommon illnesses is another key factor likely to influence market growth in the years to come. To support the biopharmaceutical sector, companies are expanding their research efforts in immunotherapeutic drugs.

Request for Analysis of COVID-19 Impact on Short Bowel Syndrome Market – https://www.transparencymarketresearch.com/covid19.php

The global short bowel syndrome market was worth around US$ 564 Mn in 2018 and is predicted to rise at 27% CAGR over the forecast timeframe, from 2019 to 2027. The market is being driven by a rise in acceptance and understanding of the treatments for short bowel syndrome. 

Key Findings of Market Report

• Increased Research and Development Activities to Improve GLP-2 Drugs

GLP-2 drugs have been improved as a result of ongoing research and development. Drug discovery efforts for the diagnosis and treatment of short bowel syndrome are growing amongst firms in the short bowel syndrome market. For example, in March 2019, Theracon AG, a global biotechnology company, declared that interim findings from its continuing phase II clinical study pertaining to apraglutide, a next-generation GLP-2 drug for the purpose of treatment of short bowel syndrome, would be released. GLP-2 drugs are becoming more widely used as a result of their benefits in minimising the burden of malnutrition and dehydration in patients and it opens up new possibilities.  Another factor likely to drive the global short bowel syndrome market over the forecast period is enhanced patient satisfaction.

Request Brochure of Short Bowel Syndrome Market Report - https://www.transparencymarketresearch.com/brochure.php

With the assistance of comprehensive preclinical optimization and characterization, firms in the global short bowel syndrome market are expanding production capacities in the formulation of synthetic GLP-2 analogues. They're attending academic forums to showcase new product innovations, which helps to boost the company's reputation in the global market for short bowel syndrome. To meet the increasing demand for options of treatment that enhance intestinal absorption, companies are developing readymade liquid formulations of GLP-2 analogue.

• Presence of Strong Pipeline Drugs for Treating the Syndrome to Support Market Growth

In the coming years, powerful pipeline drugs for short bowel syndrome are expected to provide enormous growth opportunities for the market. Glepaglutide (ZP1848), a long-acting GLP-2 analogue for short bowel syndrome, is in phase III clinical trials, with findings anticipated in 2021. The global short bowel syndrome market is likely to be driven by the presence of pipeline drugs for the condition. Many first drugs that are safe and effective for patients with short bowel syndrome are in late-stage clinical development. Because these drugs are more effective than their existing counterparts, the short bowel syndrome market is projected to expand rapidly once they are released.

Purchase the Short Bowel Syndrome Market Report - https://www.transparencymarketresearch.com/checkout.php

Short Bowel Syndrome Market: Growth Drivers

• Pre-marketing tactics utilized by players in the global short bowel syndrome market to raise awareness about the condition and its treatment options are likely to add to the growth of the market in North America.
• Rising demand for biobetter drugs and therapeutic drugs for rare conditions is likely to propel growth of the market. To strengthen the biopharmaceutical business, manufacturers are expanding their research efforts in immunotherapeutic drugs.

Request for Custom Research - https://www.transparencymarketresearch.com/custom-research.php

Global Short Bowel Syndrome Market: Key Competitors

• GLyPharma Therapeutic, Inc. (Pfizer Inc.)
• Zealand Pharma A/S
• Emmaus Life Sciences, Inc.
• Shire plc (Takeda Pharmaceutical Company Limited)
• Naia Pharmaceuticals, Inc.
• Sancilio & Company, Inc.

Explore Transparency Market Research's award-winning coverage of the global Healthcare Industry:

Parenteral Nutrition Market: https://www.transparencymarketresearch.com/parenteral-nutrition-market.html

Drug Discovery Technologies Market: https://www.transparencymarketresearch.com/drug-discovery-technologies.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."

Browse More Upcoming Reports by Transparency Market Research: https://www.transparencymarketresearch.com/upcoming.htm

Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: [email protected] 
Press Release Source: https://www.transparencymarketresearch.com/pressrelease/short-bowel-syndrome-market.htm 
Website: https://www.transparencymarketresearch.com/

SOURCE Transparency Market Research